ArticleBMC geriatrics2023
Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions.
Article in BMC geriatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Effectiveness of a hierarchical pharmacist management model on reducing hyperphosphatemia in hemodialysis patients in China: a multicenter randomized study.Scientific reports · 2026Trial
- Evaluating Clinical Pharmacy Services in Ministry of Health Hospitals in Al-Baha Region of Saudi Arabia, a Three-Year Retrospective Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Impact of clinical pharmacist interventions on drug-related problems in hospitalised patients with renal dysfunction: a quasi-experimental study.Scientific reports · 2026Article
- Drug-related problems in pediatric patients with chronic kidney disease: A single-center prospective study.Experimental and therapeutic medicine · 2026Article
- Medication Therapy Problems in Hospitalized Patients with Decreased Kidney Function Across the Spectrum of Kidney Disease: A Scoping Review.Journal of clinical medicine · 2026Review
- Classifying drug-related problems of neurodegenerative diseases in the physician-pharmacist joint clinic of neurology: an application of the PCNE method.BMC geriatrics · 2026Article
- Analysis of proton pump inhibitor-associated drug problems and contributing factors among hospitalized nephrology patients.Frontiers in pharmacology · 2026Article
- Identification of Drug-Related Problems and Assessment of Health-Related Quality of Life in Elderly Multimorbid Inpatients with Stroke.Integrated pharmacy research & practice · 2026Article
- Drug-related problems and their determinants among stroke patients in suburban China: a PCNE-based analysis with targeted initiatives.Frontiers in public health · 2026Article
- A Novel Screening Method to Prioritise Cardiovascular Patients Receiving a Pharmaceutical Care Intervention and the Effects on Patients' Difficulties with Managing Their Drug Treatment.Patient preference and adherence · 2025Article
- Effectiveness of a pharmacist-led tele-psychiatric clinic in managing drug-related problems.Journal of pharmaceutical policy and practice · 2025Article
- Addressing Glucocorticoid-Related Problems with the Clinical Pharmacist Collaboration in Rheumatology Practice: A Prospective Follow-Up Study.Rheumatology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with chronic kidney disease (CKD) are at high risk of drug-related problems (DRPs) because of extensive comorbidities and pharmacokinetic changes. This study aimed to identify DRPs and possible contributing factors in hospitalized patients with CKD, and evaluate the efficacy of the clinical pharmacist services in detection and intervention of DRPs in a large general hospital in Zhejiang Province, eastern China.
methodsWith the approval of the Ethics Committee, patients with CKD admitted to the nephrology ward from January to December 2020 were enrolled in this prospective study. The clinical pharmacist identified and intervened the DRPs during hospitalization. The DRPs were classified using the Pharmaceutical Care Network Europe (PCNE) DRP classification system, and all data were statistically analyzed using Statistical Package for Social Science (SPSS) version 26.0.
resultsA total of 914 patients with CKD were included, with 463 DRPs observed among 420 (45.95%) participants; the average DRP per patient was 0.51 (standard deviation [SD], 0.60) before pharmacist intervention. Treatment safety accounted for the highest proportion of problems (43.84%), followed by treatment efficacy, accounting for 43.20%. Drug selection was the most common cause of DRPs (60.26%), and antibiotics and cardiovascular agents were the most common drugs associated with DRPs (32.84% and 28.66%, respectively). A total of 85.53% of pharmaceutical intervention recommendations were followed, and 84.23% of DRPs were completely resolved after intervention by the clinical pharmacist. The proportion of patients who experienced DRPs decreased to 7.77%, with an average of 0.08 (SD 0.28) DRPs during hospitalization after pharmacist's intervention. Significant contributing factors for DRPs were CKD stage 4, number of comorbid diseases, number of prescribed medications, and hospitalization days in both the univariate and multivariate logistic regression models.
conclusionDRPs are common among hospitalized patients with CKD in China. CKD stage 4, the number of comorbidities, use of multiple prescription drugs, and extended length of hospital stay are contributing factors for DRPs. Even only one clinical nephrology pharmacist in the nephrology ward, clinical pharmacist can play an important role in facilitating the identification of DRPs in patients with CKD and assisting physicians resolve DRPs in this single center study in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.